Cantor Fitzgerald Has Lowered Expectations for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price

Zevra Therapeutics (NASDAQ:ZVRA) had its price target reduced by Cantor Fitzgerald from $25.00 to $19.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target would indicate a potential upside of 102.11% from the stock’s previous close.

ZVRA has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Canaccord Genuity Group dropped their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, July 27th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.00.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA traded down $1.76 during trading on Friday, hitting $9.40. 1,734,649 shares of the company were exchanged, compared to its average volume of 1,224,696. The company has a market cap of $559.45 million, a PE ratio of 7.95 and a beta of 1.01. Zevra Therapeutics has a 52-week low of $8.01 and a 52-week high of $15.03. The stock has a 50 day moving average of $11.06 and a 200 day moving average of $10.83.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. Zevra Therapeutics had a return on equity of 54.64% and a net margin of 52.80%. The business had revenue of $37.76 million during the quarter, compared to the consensus estimate of $37.08 million. Sell-side analysts forecast that Zevra Therapeutics will post 0.88 EPS for the current fiscal year.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Neil McFarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer directly owned 417,225 shares of the company’s stock, valued at $4,693,781.25. The trade was a 4.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is owned by corporate insiders.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ZVRA. Integrity Alliance LLC. acquired a new stake in Zevra Therapeutics in the 3rd quarter valued at about $10,292,000. Dimensional Fund Advisors LP raised its position in Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after acquiring an additional 400,336 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after acquiring an additional 206,543 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Zevra Therapeutics in the second quarter valued at about $2,846,000. Finally, Globeflex Capital L P purchased a new stake in shares of Zevra Therapeutics in the second quarter valued at about $2,752,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.